- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03194295
Activating Community Support for Substance Users
Activating Personal Network Support in Treatment Seeking Substance Users
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Bayview Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (for the ATS participant):
- ATS treatment participation of more than 4-weeks
- Submission of at least one drug-positive urine sample
- Expressed willingness to include a drug-free support person in treatment
Exclusion Criteria (for the ATS participant):
- Pregnancy
- Acute medical problem that requires immediate and intense medical management (e.g., AIDS defining illness; unstable diabetes)
- Presence of a formal thought disorder, delusions, hallucinations, or imminent risk of harm to self or others
- Unable to read.
Exclusion Criteria (for the CSPs)
- Submission of a drug-positive urine sample
- Pregnancy
- Acute medical problem that requires immediate and intense medical management (e.g., AIDS defining illness; unstable diabetes)
- Presence of a formal thought disorder, delusions, hallucinations, or imminent risk of harm to self or others
- Unable to read.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Community Support Intervention
Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Community Support Intervention Group, which requires methadone maintenance treatment (MMT) participants to attend the group with a drug-free family member or friend (community support person; CSP).
|
This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities.
Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant.
The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities.
For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
|
|
Active Comparator: Standard Care
Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Substance Use Disorder Educational Group as an attention-control for the intervention described in the experimental condition.
|
This 12-week educational group is designed as an attention-control group.
Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness.
Participants will be assigned 2 homework assignments each week based on the topic.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perceived social support for designated CSP as assessed by the Quality of Relationships Inventory (QRI) "support scale"
Time Frame: Monthly for 3 months
|
The investigators anticipate that Community Support (vs.
Standard Care) participants will enjoy greater levels of perceived social support (QRI "support" scale, a continuous measure) at the 3-month evaluation.
Mixed model analyses will be used to evaluate condition differences over time (Baseline, Months 1-3).
The two remaining QRI subscales ("conflict"; "depth") will also be examined using a similar analytic approach.
|
Monthly for 3 months
|
|
Behavioral and attitudinal support for abstinence as assessed by the IPA
Time Frame: Monthly for 3 months
|
The investigators anticipate Community Support (vs.
Standard Care) participants will enjoy more Behavioral and Attitudinal support for Abstinence (IPA scales; continuous measures) over the 3-month evaluation.
Mixed model analyses will be used to evaluate condition differences over time (Baseline, Month 3).
The remaining IPA subscales (Social Support for Drug Use; Behavioral Support for Drug Use; Attitudinal Support for DrugUse) will be examined in secondary analyses using a similar approach.
|
Monthly for 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Substance use and problem severity as assessed by urinalysis testing and Addiction Treatment Index (ASI) composite scores
Time Frame: Monthly for 3 months
|
The investigators anticipate Community Support (vs. Standard Care) participants will have lower rates of "any" drug-positive urine samples (i.e., opioid, cocaine, sedatives, and/or cannabis) over the 3-month evaluation. Drug-positive urine samples will be treated as a dichotomous variable. Generalized estimating equation (GEE) analysis will be used to evaluate condition differences over time (Baseline, Months 1-3). Specific classes of drugs (opioid, cocaine, sedative, cannabis positive urinalysis tests) will be examined using a similar analytic approach. Secondary analyses will use mixed model analyses to evaluate condition differences in ASI self-report drug composite scores over time (Baseline, Months 1-3). The remaining ASI composite scores will be examined using a similar approach. |
Monthly for 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Kidorf, Ph.D., Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00130614
- 1R34DA042320-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use Disorders
-
University of ArkansasNational Center for Advancing Translational Sciences (NCATS)RecruitingParenting | Substance Use Treatment | Perinatal Substance UseUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Use Disorder | Substance Use Disorder (SUD)United States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Substance Use Disorders | Cannabis Use | Alcohol Use, UnspecifiedUnited States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
Indiana UniversityNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use Disorders | Nicotine Use DisorderUnited States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)Active, not recruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Substance Use DisordersUnited States
-
Spark Biomedical, Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA); Baylor College... and other collaboratorsRecruitingSubstance Use Disorders | Alcohol Use Disorder | Alcohol Abuse | Substance Use Disorders Alcohol Use Withdrawal StateUnited States
Clinical Trials on Community Support Intervention Group
-
The University of Hong KongActive, not recruitingPre-diabetesHong Kong
-
University of Central FloridaAlzheimer's and Dementia Resource CenterCompletedDementia | Alzheimer's DiseaseUnited States
-
Elizabeth Glaser Pediatric AIDS FoundationMinistry of Health and Child Welfare, Zimbabwe; The Children's Investment Fund...CompletedHIV-infection/Aids
-
NMP Medical Research InstituteMacmillan Research Group UKCompleted
-
McMaster UniversitySt. Joseph's Healthcare HamiltonRecruitingPsychosis | Bipolar Disorder (BD)Canada
-
Public Health - Seattle and King CountyNational Institute of Environmental Health Sciences (NIEHS)Completed
-
University of RochesterNational Institute of Mental Health (NIMH)Completed
-
Emory UniversityUniversity of California, San Francisco; National Institute of Environmental... and other collaboratorsActive, not recruiting
-
University of the PhilippinesPhilippine Dermatological SocietyCompleted